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Summary
Aim: Analysis of the global neurotic symptom dynamics during intensive integrative 
psychotherapy in a day-hospital setting, and its relation to the treatment outcome. 
Method: 4345 symptom check-lists SCL“0", filled in by 319 patients treated in the 
years 1990-1998 were analysed. The studied group consisted of235 women and 84 men 
suffering from somatization disorders, generalized anxiety disorder and dissociative dis­
orders. 
Results: In groups of patients with different therapy outcome, different types of se­
quential changes of global symptom level (“GST") were observed. Some phenomena like 
for example unchanged symptom level ("plateau ") lasting for a few weeks, occurred with 
different frequency - related to the final therapy outcome. Decrease of the global symp­
tom level below 200 points in women and 165 points in men often preceded global symp­
tom exacerbation and occurred even in therapies with non-beneftcial final results. 
Conclusion: Some aspects of the global neurotic symptom dynamics may be treated as 
additional markers of beneficial or non-beneficial therapy processes. Sequences of symp­
tom decreases, as well as sequences of short increases were connected to better final 
results. Weekly measurements of the symptom level (with the use of checklists) may be 
useful for monitoring the psychotherapy process, but the decrease of the GSL to the val­
ues typical for the healthy population does not permit one to consider a patient as a 
"cured" one. Even decrease of GSL below 100 (women) /82 (men) points was not always 
connected to its further stability. 
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Introduction
In the last decade a lot of attention of psychotherapy researchers was given to the 
change of the global symptom intensity and its course during treatment, especially 
that regarding relation between symptom fluctuation and the final therapy outcome - 
in terms of possibility of prediction of the therapy outcome. A wider review of litera­
ture was presented in a separate paper [1]. 
The purpose of the study was an analysis of dynamics of the global symptom level 
during psychotherapy of neurotic patients, and research on the relation between the 
observed dynamics and therapy outcome. 
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Material and methods
The material studied was 4345 symptom checklists, filled in by 319 patients treat­
ed in a day hospital of the Wojewódzki Ośrodek Leczenia Nerwic in Cracow, in the 
years 1990-1998. In the group studied there were 235 women and 84 men: 103 pa­
tients with a diagnosis of somatoform disorders, mostly somatization disorders (F45. 0), 
82 with a diagnosis of generalized anxiety disorders (F41. 1), 63 patients with diagno­
sis of dissociative motor disorders (F44. 4) and dissociative anaesthesia and sensory 
loss (F44. 6) and 71 patients with diagnoses combining the elements of the disorders 
listed above. In all the patients, the value of the symptom checklist SCL “0”, filled in 
during preliminary ambulatory examinations, exceeded 165 points for men and 200 
points for women. The documentation of the global symptom intensity in a minimum 
of 9 weeks was considered as complete. The patient’s age was 18-56 years (mean = 
35. 8, median = 36, SD = 8. 16). 
Data from symptom checklists “0” (SCL“0”) filled in by patients before treat­
ment (during consultation), on the first day of treatment, on every Monday of the 
week and on the last day of treatment were analysed. Comparison of global symptom 
level from the first and the last day of treatment reflected on the therapy outcome, 
while data from weekly measurements indicated changes of global symptom intensi­
ty in the course of treatment. 
Global symptom change was categorized (see also [2]) as “significant symptom 
improvement”, “lack of symptom improvement”, and “symptom deterioration”. Ob­
taining up to 100 points for women and 82 for men, was assumed as “symptom cure”, 
due to criteria twice more rigorous than clinical ones, resulting from the “cut-off 
point” [3, 4]. Patients were divided into three groups according to the final outcome: 
A - significant improvement with symptom cure (129 patients - 40. 4%), B - signifi­
cant improvement without cure (100 patients - 31. 3%) and C - lack of symptom 
improvement (87 patients - 27. 3%). Two patients with a low level of global symptom 
intensity (at pre-therapy period) where a statistically insignificant decrease would 
lead to obtaining “symptom cure”, as well as one case of significant deterioration 
were excluded from further analyses. 
In a pilot study the dynamics of global symptom intensity was assessed for each 
patient and their comparison was conducted. On that basis categories of global symp­
tom level (“GSL”) changes were proposed as shown in Table 1. 
The frequency of each type of GSL change defined in Table 1 was calculated for 
each patient, resulting in a parameter independent from the duration of treatment. In 
the next step distributions of GSL changes in the three groups (A, B, C) calculated for 
each patient underwent the comparative analysis. Comparison of the three distribu­
tions was conducted with the use of Kruskal-Wallis test, in the case of significant 
main effect, pairs of distributions were compared with the median test. Rates of pa­
tients with particular characteristics of symptom dynamics were compared with the 
two-tailed fraction test (results are shown in Table 3). 
Results
Already in the pilot study it appeared that only in two cases (two patients) alter­
ations of the courses were monotonic, the rest differed not only among groups of 
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different effects of treatment but also within those groups. Complexity of the global 
symptom level dynamics is illustrated by dissemination of particular categories of the 
GSL change shown in Table 2 and 3. 
Table 1 
Categories of change observed in the course of therapy
Category Definition of changes of global symptom level (“GSL”)
Increase Increase by more than 5% of the previous value of GSL
Decrease Decrease by more than 5% of the previous GSL value
Sequence increase - decrease Increase of GSL followed by decrease
Sequence decrease - increase Decrease of GSL followed by increase
Plateau Change by less than 5% of the previous GSL value
“High” plateau As above, GSL above 200/165 pts
2 (3,4) succeeding increases Sequence of 2 (3,4) increases
2 (3,4) succeeding decreases Sequence of 2 (3,4) decreases
2 (3,4) succeeding plateau Sequence of 2 (3,4) plateau
Decrease of GSL to the value typical 
for the healthy population and following 
increase to the value typical for neurotics
Decrease of GSL below 200 pts. (women), or 165 pts. (men), 
then increase above 200/165 pts.
Decrease of GSL to half of the value typical 
for the healthy population and following 
increase to the value typical for neurotics
Decrease of GSL below 100 pts. (women), or 62 pts. (men), 
then increase above 200/165 pts.
Table 2 
Dissemination of GSL changes in groups A, B, C.
Medians (in brackets values of the lower and upper quartile)
Frequency: Group A (n=129) Group B(n=100) Group C (n=87) Kruskal-Wallis Test Median tests
Plateaus (all) ©@0.11(0.06-0.18)
©0.21
(0.1-0.3)
@0.22
(0.1-0.33) p<0.0001
©<0.0001 
@<0.0005
“High” plateau (GSL above 0® 0.07 ©0.2 @0.2 p<0.0001 ©<0.0001200/165 pts.) (0-0.11) (0.09-0.3) (0.09-0.33) @<0.0005
2 succeeding ‘high” plateaus ©@0(0-0) ©0(0-0.08) @ 0 (0-0.06) p<0.0001 © @<0.0001
Increases (all) @0.27
(0.18-0.33)
@0.23
(0.18-0.33)
@®0.33
(0.25-0.4) p<0.0001
©<0.0005
@<0.0001
Decreases (all) ©®0.6(0.55-0.67)
®@ 0.52
(0.46-0.62)
®@ 0.44 
(0.33-0.5) p<0.0001
©<0.0001 
@@<0.0005
Sequences increase - decrease 0.18(0.12-0.25)
0.16
(0.09-0.21)
0.18
(0.10-0.25) ns ns
Sequences decrease - increase 0.17(0.09-0.22)
0.15
(0.10-0.20)
0.17 
(0.10-0.24) ns ns
Decrease of GSL below 200/165 ©@0.25 ®@ 0.06 ®@0 p<0.0001 ©@<0.0001pts obtained during therapy (0.15-0.39) (0-0.13) (0-0.08) @<0.005
Decrease of GSL below 100/82 ©@0.1 ©0 @0 p<0.0001 ©@<0.0001pts. obtained during therapy (0-0.23) (0-0) (0-0)
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Dissemination of GSL change in groups A, B, C
Table 3
Rate of patients with a particular category 
of GSL dynamics Group A (n= 129) Group B (n=100) Group C (n=87) Two fractions test
2 succeeding "high" plateaus 13(10%©®) 44 (44%©) 33 (38%®) ©@<0.0001
3 succeeding “high" plateaus 4 (3%©) 4 (4%®) 12(14%®®) ®<0.005®<0.05
4 succeeding “high" plateaus 1 (0.5%®) 3 (3%) 4 (5%®) ®<0.05
5 succeeding “high” plateaus 0© 1 (1%) 3 (3%®) ®<0.05
6 succeeding “high" plateaus 0 0 1 (1%) ns
2 succeeding increases 48 (37%®) 35 (35%®) 48 (55%®®) ®®<0.01
3 succeeding increases 7 (5%ffl) 5 (5%) 11 (13%®) ®<0.05
Decrease of GSL Io the value typical for 
the healthy population followed by 
increase above 200/165 pts
48 (37%® 0) 22 (22%®) 20 (23%®) ©@<0.05
one time 20(16%) 13(13%) 11 (13%) ns
two times 10 (8%ffi) 2 (2%®) 2 (2%) ©<0.05
three times 7 (5%) 4 (4%) 2 (2%) ns
four times 3 (2%) 0 0 ns
five times 5 (4%) 1 0%) 1 (1%) ns
more than five times 3 (2%) 2 (2%) 4 (5%) Ns
Decrease of GSL to half of the value 
typical for the healthy population and 
following an increase above 200/165 pts
6 (5%) 1 (1%) 1 (1%) Ns
Discussion
Lack of change of GSL, especially lack of several following “high” plateaus (i.e. 
stagnation) was the scarcest in group A (differences statistically significant; see Ta­
bles 2 and 3). For patients from group C, the increase in GSL was significantly more 
frequent than in patients from groups A and B (see Table 2). An increase in symptoms 
was noted at least once in almost all the patients in each of the groups (non-significant 
statistically), however sequences of GSL peaks lasting for a few weeks in the whole 
course of therapy (most frequent in group C, Table 3) were present at least once in 30- 
50% of the patients in each group. A drop in the GSL occurred the most frequently in 
patients from the group obtaining the best final results (A), less frequently in the 
group B and were the least frequent in C (decreases were generally frequent). In the 
group of patients who obtained significant improvement with symptom cure change 
by less than 5% between two succeeding measurements (plateau) was much more 
seldom than in the remaining groups. A similar but less strongly marked trait was 
found in the group B. In the group C the least frequent category of GSL change was 
decrease (the most frequent in A, less in B).
The results obtained suggest some possibility of considering combinations of GSL 
plateaus and increases with concurrent lack of numerous decreases (a combination 
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that was seldom in group A, more frequent in B and very often in C) as a kind of 
prognostic trait - unfavourable for the outcome. They do not however, provide the 
possibility of indicating a typical, successful or unsuccessful, course of treatment. 
The observations conducted do not support also the monotonic character of changes 
that is often mentioned in literature (more [1]).
Frequency of sequences of the GSL increase followed by a decrease of symptoms 
as well as sequences of decrease and a following increase of GSL, were similar in 
patients in all three groups (A, B, C, no significant differences, see Table 2).
A decrease of GSL below 200/165 points obtained in the course of treatment was 
very frequent in therapies of patients from group A, and lasted for about of 25% of the 
duration of their treatment, much less frequent (however also obtained) in the remain­
ing groups (B and C, Table 2 and 3). It seems to be worth underlining that in the case 
of 90 from the 319 patients, from all the three groups, a repeated significant increase 
of GSL under 200/165 points (table 3) was found even several times during treat­
ment. A similar, however much more infrequent phenomenon (8 of 316 cases) of 
GSL below 100/82 pts. (values of 99, 89, 85, 79, 77, 61, 60 and even 24 points) 
happened in all groups, even in one therapy finished with “lack of symptom change” 
(Table 3).
As the results show, only frequent measurement of GSL and assessment of its 
individual change may contribute to therapy process monitoring. Such a manner of 
therapy observation may be used for defining the moment of the best improvement or 
defining which phenomena observed in the course of treatment (“intermediated re­
sults” as defined by Kiessler) might serve as a kind of “prediction” traits of the final 
outcome [1, 5, 6, 7].
In this paper, aimed at searching for connections between neurotic disorder symp­
tom dynamics and treatment outcome, similar methods to those known for example 
from K.Howard group’s studies [i.e. 8, 9, 10] based on distinctive characteristics of 
change during therapy of individual patients [e.g. 11] were used. This particular method 
was applied to avoid possible misinterpretation resulting from summing curves and 
data aggregation [8, 12, 13, 14] that appear in the mean change analysis calculated for 
whole groups of subjects.
However predicting the final outcome on basis of similarity of succeeding ques­
tionnaires (e.g. GSL) to analogous questionnaires from therapies whose results are 
already known, is theoretically possible, however assuming that for example five 
following weekly measurements [5, 6] may contribute to the forecasting of the treat­
ment outcome as “already determined”, does not seem justifiable. Besides, as is to be 
found in literature, the proposed methods fail to predict treatment outcome in about 
25% of the patients [e.g. 15]. It seems obvious that even if the possibility of such a 
prediction strengthens along with the length of the observed therapy, final results 
remain undetermined to the last day of treatment. Such an assumption is also support­
ed by the author’s own analyses which showed that only in the second part of the 
psychotherapy, more statistically significant differences in symptom dynamics in groups 
of different treatment outcome both in distinctive symptoms [16] and - as known 
from the pilot research - in global symptom level (GSL), were observed. A similar 
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conclusion derives also from the described observation of the course of GSL changes 
during therapy. Obtaining a decrease of GSL down to values typical for people not 
suffering from neurotic disorders (below 200/165 points) was not necessarily con­
nected to obtaining symptom cure as the final outcome - in many cases global symp­
toms intensity increased once again. What’s more, even obtaining a GSL decrease 
below 100/82 points, not always resulted in maintaining such a low level of symp­
toms or completing treatment with symptom cure. It raises a question if any low level 
of neurotic complaints (symptoms) may serve as basis to recognise the treatment as 
successful and to make a decision to end treatment, when the criterion of “case iden­
tification” in epidemiology (200/165 points) seems to be not entirely reliable and 
even a twice as much strict criterion (100/82 points) does not guarantee maintaining a 
satisfying therapy outcome. It is impossible to conclude that an analogous phenome­
non is characteristic for the whole population of patients suffering from neurotic dis­
orders - symptom dynamics may depend on many variables like treatment conditions, 
kind of therapy, theoretical treatment assumptions, intensity and information and ex­
pectations, the proclaimed duration of treatment etc.
Results of analyses of symptom change dynamics may also depend on the fre­
quency of measurement. Too long intervals between surveys make observation of 
symptom fluctuation impossible, on the other hand too frequent measurements may 
lead to unreliability of results caused by the “training effect” or tiredness and dejec­
tion of a too excessive task performance etc. resulting in mechanical answering [17]. 
The recommended solution, enabling omitting such mistakes, is to apply symptom 
checklists once a week. Assumption of lack of the “training effect” in such a case is 
supported by excessive variety of GSL fluctuations that was observed also in the 
present research.
The possibility of prediction how GSL changes influence the final treatment out­
come is limited also by a specific character of symptom checklists composition - by 
necessity omitting many symptoms. Different results of different symptom checklists 
filled at the same time by the same patient may be significantly distinct because of 
different sets of variables included [18, 19]. Moreover, information based only on 
fluctuation of GSL may blur some aspects of particular symptom dynamics because 
of opposite direction or different occurrence of their changes in the course of time. 
Perhaps this is why - despite initial assumptions - no connection was found between 
sequences of “increase followed by decrease” and “decrease followed by increase” of 
GSL and outcome.
The way the checklist was applied (due to the instruction, patients report a change 
in the past seven days) disables identification of symptoms that lasted only for several 
days, hours or just temporary fluctuations - too short to influence the global assess­
ment of the whole week. Patients who finished therapy as “symptom cured” (group 
A) reported a high and stable GSL for several weeks more seldom than patients from 
other groups. GSL courses were connected both to more frequent decreases of GSL 
than in the other groups and - even slightly more frequent than in the case of patients 
who obtained “significant improvement without symptom cure” - increases of global 
symptom intensity. That might be caused for example by raising problems during 
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group sessions analogous to those of a given patient, resignation from avoiding ex­
ploration of potentially “dangerous” areas of self-experience, obtaining insight, at­
tempts to change everyday functioning (working through) etc. [11]. Symptoms with­
drawal in those patients may indicate that conditions of their treatment were propi­
tious (interventions adequate to the kind of disorder and applied in the right time, 
promoting insight and working through, change of cognitive schemata and dysfunc­
tional behaviour). It cannot be excluded that a progressive decreasing of GSL without 
any increases (described among others by M. Lambert e.g. [5]), evidence only pa­
tients’ satisfaction with being in a “therapeutic” environment that somehow gratifies 
neurotic needs.
Perhaps some of the observed phenomena were connected to a specific manner of 
the therapists’ functioning. One of the principles of applied eclectic, psychodynami- 
cally oriented understanding of psychopathology and psychotherapy was stimulating 
the patient towards obtaining insight into difficult, tension-provoking, unconscious 
experiences. Approaching such areas usually increases symptom intensity while ob­
taining insight and working through leads to their removal. It cannot be excluded that 
providing patients with the feedback regarding the level of their symptom intensity 
(patients had graphs of every-week GSL change to their disposal), influenced the 
direction of change, e.g. observation that some increases in other patients were tem­
porary, mobilized some patients to confront with a symptom provoking context (situ­
ations and behaviours).
In group B - patients who obtained improvement without symptom cure, the least 
number of all GSL increases and increases in 2 and 3-week sequences was observed. 
While considering different aspects of GSL dynamics, this group seems to be “in 
between” groups A and C - in respect of number of GSL plateaus and decreases, as 
well with regard to the kind of changes at the end of therapy (in this aspect group B 
seems to be more similar to C). It is interesting that those patients entered the treat­
ment with higher GSL. This may be a confirmation of a belief that the higher intensity 
of symptoms the more difficult it is to obtain therapeutic success [e.g. 20]. It has no 
direct connection to the degree of improvement expressed as a mathematical remain­
der between initial and final value of GSL. Obtaining “bigger improvement” in pa­
tients beginning treatment with higher symptom intensity is said to be easier because 
“there is what is to be cured” [21]. It results in an assumption (and even trials of 
predicting outcome on the basis of initial severity of symptoms reported by patients in 
symptom checklists SCL-90R or OQ-45) that patients with a high level of symptom 
intensity obtain better treatment effects [8, 22-28]. Results of the presented analysis 
do not confirm that assumption.
In the group of “lack of changes” (C) the occurrence of several succeeding “high 
plateaus” (unchanged high level of GSL) was significantly more frequent than in 
other groups which indicates probably some kind of impasse in the course of treat­
ment. Despite not large differences in the GSL value measured at pre-treatment level 
and on the last day of treatment, in the course of such therapies numerous, small 
increases and sometimes decreases of GSL, even down to the level typical for the 
healthy population were observed.
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On the ground of the results obtained in the presented work it is impossible to 
agree with M. Lambert who claimed [e.g. 5, 6] that only decreases of GSL (observed 
during treatment) are characteristic for successful therapies. It seems that it is more 
proper to assent a less frequent occurrence of GSL plateaus as a predictor of obtain­
ing good outcome. Probably periods of lack of GSL fluctuation (plateaus) may also 
serve as a predictor of unfavourable treatment results, especially when considering 
high levels of GSL. The author agrees with the opinion that occurrence of the lack of 
changes in GSL should be an indication of supervision necessity [14, 20, 29-33J.
The results show that the way the improvement was obtained, at least in therapies 
analysed in this research, it consisted mostly of GSL escalations interlaced by de­
creases and short periods of stagnations (plateaus). Thus it seems that no characteris­
tics of neurotic symptom dynamics may serve as a certain premise to acknowledge 
treatment as purposeless. It should be repeated after Z. Martinovich [34] (on a basis 
of single case analyses) - not to precipitately classify the process of therapy as augur­
ing its unfavourable termination. Also obtaining considerable reduction of GSL can­
not be the only premise of decision for treatment termination.
Conclusions
1. Changes of global neurotic symptom level (indicated by fluctuations of GSL mea­
sured in succeeding weeks of therapy) were the most apparent in patients who 
completed therapy as “symptom cured and significantly improved”, the least in 
those who obtained no improvement.
2. In the group of patients with best treatment outcome, periods of stagnancy in 
symptom fluctuations (plateaus) were the rarest.
3. Decrease of GSL - during therapy - to values below 200 points (women) or 165 
points (men) may not serve as a guarantee that in the succeeding weeks of treat­
ment a significant increase of symptoms will not occur. This is why the decision 
about treatment termination should not rely only on a decrease of GSL to the level 
typical for the untreated population and even to values twice lower.
4. Neurotic symptom dynamics in the course of psychotherapy is only one of the 
phenomena contributing to the final treatment result and prediction of the out­
come based solely on the basis of its observation is not possible.
The presented research was not sponsored. Polish version was also published [35].
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